Partial progress: Governing the pharmaceutical industry and the NHS, 1948-2008

Journal of Health Politics, Policy and Law

Volumn 34, Issue 6, 2009, Pages 931-977

  Abraham, John ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONFLICT OF INTEREST; COST-BENEFIT ANALYSIS; DRUG INDUSTRY; DRUG UTILIZATION; GOVERNMENT REGULATION; GREAT BRITAIN; HEALTH SERVICES ACCESSIBILITY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MARKETING OF HEALTH SERVICES; NATIONAL HEALTH PROGRAMS; POLITICS; PRODUCT SURVEILLANCE, POSTMARKETING; SOCIOLOGY, MEDICAL;

EID: 73249142317     PISSN: 03616878     EISSN: 15271927     Source Type: Journal    
DOI: 10.1215/03616878-2009-032     Document Type: Review

References (161)

1. Abel-Smith, B. 1985. Who Is the Odd Man Out? The Experience of Western Europe in Containing Costs of Health Care. Milbank Memorial Fund Quarterly: Health and Society 63:1-17.
2. Abraham, J. 1994a. Bias in Science and Medical Knowledge. Sociology 28:717-736.
3. -. 1994b. Negotiation and Accommodation in Expert Medical Risk Assessment and Regulation. Policy Sciences 27:53-76.
4. -. 1995a. The Production and Reception of Scientific Papers in the Medical-Industrial Complex. British Journal of Sociology 46:167-190.
5. -. 1995b. Science, Politics, and the Pharmaceutical Industry. London: St. Martin's Press.
6. -. 2002. Transnational Industrial Power, the Medical Profession, and the Regulatory State. Social Science and Medicine 55:1671-1690.
7. Abraham, J., and C. Davis. 2005. A Comparative Analysis of Drug Safety Withdrawals in the U.K. and the U.S. (1971-1992): Implications for Current Regulatory Thinking and Policy. Social Science and Medicine 61:881-892.
8. -. 2006. Testing Times: The Emergence of the Practolol Disaster and Its Challenge to British Drug Regulation in the Modern Period. Social History of Medicine 19:127-147.
9. -. 2007. Deficits, Expectations, and Paradigms in British and American Drug Safety Assessments: Prising Open the Black Box of Regulatory Science. Science, Technology, and Human Values 32:399-431.
10. Abraham, J., and J. Sheppard. 1999. The Therapeutic Nightmare: The Battle over the World's Most Controversial Sleeping Pill. London: Earthscan/Island Press.
11. Aldcroft, D. H. 1986. The British Economy. Vol. 1, The Years of Turmoil, 1920-1951. Sussex: Wheatsheaf Books.
12. Alzheimer's Drugs Remain Limited. 2007. BBC News, August 10. news.bbc.co.uk/2/ hi/health/6939950.stm.
13. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Arlington, VA: American Psychiatric Association.
14. Association Internationale de la Mutualite (AIM), European Social Insurance Platform (ESIP), Health Action International (HAI), International Society of Drug Bulletins (ISDB), and Medicines in Europe Forum (MiEF). 2008. Legal Proposals on "Information" to Patients by Pharmaceutical Companies: A Threat to Public Health. Joint briefing paper, March 6.
15. Association of the British Pharmaceutical Industry (ABPI). 1970. Legislation: Medicines Commission. ABPI Annual Report (1969-70). London: ABPI.
16. -. 1974a. Information and Services and Public Relations: Nationalisation. ABPI Annual Report (1973-1974). London: ABPI.
17. -. 1974b. Review of the Year: Nationalisation or Public Ownership? ABPI Annual Report (1973-1974). London: ABPI.
18. -. 1977. Speeches. ABPI Annual Report (1976-77). London: ABPI.
19. -. 1993. A Guide to the Pharmaceutical Price Regulation Scheme. London: ABPI.
20. Audit Commission for Local Authorities and the National Health Service in England and Wales. 1994. A Prescription for Improvement: Towards More Rational Prescribing in General Practice (Health and Personal Social Services Report). London: Her Majesty's Stationery Office (HMSO).
21. Berg, S. 2006. Herceptin: Was Patient Power Key? BBC News, June 9. news.bbc .co.uk/2/hi/health/5063352.stm.
22. Billion-Pound Price Cut Won for NHS Medicines Bill. 2004. Northern Ireland on the Internet, November 3. www.4ni.co.uk/northern-ireland-news. asp?id=34718.
23. Binns, T. B. 1980. The Committee on the Review of Medicines. BMJ 281:1614-1615.
24. Black, N. 1997. A National Strategy for Research and Development: Lessons from England. Annual Review of Public Health 18:485-505.
25. Brennan, T. A. 1998. The Role of Regulation in Quality Improvement. Milbank Quarterly 76:709-731.
26. British Medical Association and Pharmaceutical Society of Great Britain (BMA and PSGB). 1981. British National Formulary: 1981. London: BMA and PSGB.
27. British Oncology Pharmacy Association (BOPA). 2008. Cancer Network Pharmacists Forum: Position Statement on "Risk-Sharing" in Oncology. London: BOPA.
28. Britten, N. 2008. Medicines and Society: Patients, Professionals, and the Dominance of Pharmaceuticals. New York: Palgrave Macmillan.
29. Bruce, M. 1961. The Coming of the Welfare State. London: B. T. Batsford.
30. Castellanos, F. X., P. P. Lee, W. Sharp, N. O. Jeffries, D. K. Greenstein, L. S. Clasen, J. D. Blumenthal, et al. 2002. Development Trajectories of Brain Volume Abnormalities in Children and Adults with Attention Deficit/Hyperactivity Disorder. Journal of the American Medical Association 288:1740-1748.
31. Centre for Medicines Research (CMR). 2005. Innovation on the Wane? Latest News Bulletin. Carshalton, U.K.: CMR.
32. Charles River Associates. 2004. Innovation in the Pharmaceutical Sector: A Study Undertaken for the European Commission. London: CRA.
33. Collier, J. 1985. Licensing and Provision of Medicines in the United Kingdom: An Appraisal. Lancet 326:377-381.
34. -. 1989. The Health Conspiracy. London: Century.
35. Commentary from Westminster: Adverse Reactions to Drugs. 1976. Lancet 308:1312-1313.
36. Conrad, P., and D. Potter. 2000. From Hyperactive Children to ADHD Adults: Observations on the Expansion of Medical Categories. Social Problems 47:559-582.
37. Crinson, I. 2004. The Politics of Regulation within the "Modernized" NHS: The Case of Beta Interferon and "Cost- Effective" Treatment of Multiple Sclerosis. Critical Social Policy 24:30-49.
38. CSM Interested in Computerised Monitoring of Adverse Drug Effects. 1976. Scrip, December 11, 2-3.
39. Delamothe, T. 1989. Drug Watchdogs and the Drug Industry. BMJ 299:476.
40. Dent, T. H. S., and M. Sadler. 2002. From Guidance to Practice: Why NICE Is Not Enough. BMJ 324:842-845.
41. Department of Health (DoH). 1994a. Government Response to the Second Report from the Health Committee, Session 1993-94: Priority Setting in the NHS: The NHS Drugs Budget. Cm. 2683. London: HMSO.
42. -. 1994b. Prescription Cost Analysis. London: Government Statistical Service.
43. -. 1998. A First Class Service: Quality in the New NHS. London: HMSO.
44. -. 2001. The Expert Patient: A New Approach to Chronic Disease Management for the 21st Century. London: HMSO.
45. -. 2002a. Clinical Guidance from the National Institute for Clinical Excellence: Timing and Selection of Topics for Appraisal. London: The Stationery Office (TSO).
46. -. 2002b. Cost Effective Provision of Disease Modifying Therapies for People with Multiple Sclerosis. Health service circular, HSC 2002/004. London: TSO.
47. -. 2003. Prescription Cost Analysis. London: Government Statistical Service.
48. -. 2008. High Quality Care for All: NHS Next Stage Review Final Report. Cm. 7432. London: TSO.
49. Dollery, C. T., and M. D. Rawlins. 1977. Monitoring Adverse Reactions to Drugs. BMJ 1:96-97.
50. Drug Companies Join Flu Protest. 1999. BBC News, October 6. news.bbc.co.uk/2/hi/ business/466563.stm.
51. Drummond, M., J. Cooke, and T. Walley. 1997. Economic Evaluation under Managed Competition: Evidence from the U.K. Social Science and Medicine 45:583-595.
52. Evans, J., and P. Cunliffe. 1987. Study of Control of Medicines. London: HMSO.
53. Fox, D. M. 2004. The Administration of the Marshall Plan and British Health Policy. Journal of Policy History 16:191-211.
54. Fox, N. J., K. J. Ward, and A. J. Rourke. 2005. The "Expert Patient": Empowerment or Medical Dominance? Social Science and Medicine 60:1299-1309.
55. Gabe, J., ed. 1991. Understanding Tranquilliser Use. London: Tavistock/Routledge.
56. Giaimo, S. 2002. Markets and Medicine: The Politics of Health Care Reform in Britain, Germany, and the United States. Ann Arbor, MI: University of Michigan Press.
57. Greer, S. L. 2004. Territorial Politics and Health Policy: U.K. Policy in Comparative Perspective. Manchester: Manchester University Press.
58. Griffin, J. P., and J. R. Long. 1981. New Procedures Affecting the Conduct of Clinical Trials in the U.K. BMJ 283:481.
59. Guidance over Anti-Flu Drug "Wrong." 2001. BBC News, February 15. news.bbc .co.uk/2/hi/health/1170376.stm.
60. Harding, R. 2001. Unlocking the Brain's Secrets. Family Circle, November 20, 10-11.
61. Hardy, A. 2001. Health and Medicine in Britain since 1860. New York: Palgrave.
62. Hassell, K., V. Atella, E. I. Schafheutle, M. C. Weiss, and P. R. Noyce. 2003. Cost to the Patient or Cost to the Healthcare System? Which One Matters Most for GP Prescribing Decisions? European Journal of Public Health 13:18-23.
63. Healy, D. 2004. Let Them Eat Prozac. New York: New York University Press.
64. -. 2006. The New Medical Oikumene. In Global Pharmaceuticals: Ethics, Markets, Practices, ed. A. Petryna, A. Lakoff, and A. Kleinman, 61-84. Durham, NC: Duke University Press.
65. Herxheimer, A. 2003. Relationships between the Pharmaceutical Industry and Patients' Organizations. BMJ 326:1208-1210.
66. Hodges, M. 1987. Control of the Safety of Drugs, 1868-1968. Pharmaceutical Journal 240:119-122.
67. House of Commons Health Committee (HCHC). 1994. Priority Setting in the NHS: The NHS Drugs Budget. Second Report, Session 1993-94. Vol. 1. London: HMSO.
68. -. 2002. National Institute for Clinical Excellence. Second Report of Session 2001-02. Vol. 1. London: TSO.
69. -. 2005. The Influence of the Pharmaceutical Industry. Fourth Report of Session 2004-05. Vol 1. London: TSO.
70. -. 2008. National Institute for Health and Clinical Excellence: First Report of Session 2007-08. HC 27-1. London: TSO.
71. Joint Committee on Prescribing (Great Britain and Scotland). 1950. Ministry of Health/Department of Health for Scotland and Central Health Services Council: The Second Interim Report of the Joint Committee on Prescribing. London: HMSO.
72. Klein, R. 2006. The New Politics of the NHS: From Creation to Reinvention. Oxford: Radcliffe Publishing.
73. Lexchin, J. 1993. Interactions between Physicians and the Pharmaceutical Industry. Journal of the Canadian Medical Association 149:1401-1407.
74. -. 2006. The Pharmaceutical Industry and the Pursuit of Profit. In The Power of Pills, ed. J. C. Cohen, P. Illingworth, and U. Schuklenk, 11-24. London: Pluto.
75. Lexchin, J., L. A. Bero, B. Djulbegovic, and O. Clark. 2003. Pharmaceutical Industry Sponsorship and Research Outcomes and Quality. BMJ 326:1167-1170.
76. Light, D. W. 1995. Countervailing Powers: A Framework for the Professions in Transition. In Health Professions and the State in Europe, ed. T. Johnson, G. Larkin, and M. Saks, 25-43. London: Routledge.
77. -. 2001. Managed Competition, Governmentality, and Institutional Response in the United Kingdom. Social Science and Medicine 52:1167-1181.
78. Light, D. W., and D. Hughes. 2001. A Sociological Perspective on Rationing. Sociology of Health and Illness 23:551-569.
79. Lumley, C. E., S. R. Walker, G. C. Hall, N. Staunton, and P. R. Grob. 1986. The Under-Reporting of Adverse Drug Reactions Seen in General Practice. Pharmaceutical Medicine 1:205-212.
80. Mann, R. D. 1984. Modern Drug Use: An Enquiry on Historical Principles. Lancaster: MTP Press.
81. McGuire, W. L. 2005. Beyond EBM: New Directions for Evidence-Based Public Health. Perspectives in Biology and Medicine 48:557-569.
82. McIntyre, A. 1999. Key Issues in the Pharmaceutical Industry. Chichester: John Wiley.
83. Medawar, C., and A. Hardon. 2004. Medicines out of Control? Antidepressants and the Conspiracy of Goodwill. Amsterdam: Askant.
84. Medawar, C., E. Rassaby, and B. Guthrie. 1992. Power and Dependence. London: Social Audit.
85. Medicines and Healthcare Products Regulatory Agency (MHRA). 2008. Delivering High Standards in Medicines Advertising Regulation: Annual Report September 2007-August 2008. London: MHRA.
86. Middlemas, K. 1979. Politics in Industrial Society: The Experience of the British System since 1911. London: Andre Deutsch.
87. Millar, J. S. 2001. Consultations Owing to Adverse Drug Reactions in a Single Practice. British Journal of General Practice 51:130-131.
88. Ministers Seek to Cut NHS Drugs Budget. 2008. ePolitix.com, January 7. www.epolitix .com/latestnews/article-detail/newsarticle/ministers-seek-to-cut- nhs-drugs -budget/?no-cache=1.
89. Mold, A., and V. Berridge. 2007. Crisis and Opportunity in Drug Policy: Changing the Direction of British Drug Services in the 1980s. Journal of Policy History 19:29-48.
90. Navarro, V. 1994. The Politics of Health Policy: The U.S. Reforms, 1980-1994. Cambridge, MA: Blackwell.
91. New, B. 1996. The Rationing Agenda in the NHS. BMJ 312:1593-1601.
92. News and Notes: Parliament, Questions in the Commons: Pharmaceutical Industry. 1976. BMJ 2:1397.
93. NHS Drug Costs to Be Renegotiated. 2007. BBC News, August 2. news.bbc.co.uk/2/ hi/health/6927814.stm.
94. NICE (National Institute for Clinical Excellence). 1999. National Institute for Clinical Excellence: Framework Document. London: NICE.
95. -. 2002. Beta Interferon and Glatiramer Acetate for the Treatment of Multiple Sclerosis. Technology appraisal guidance series, no. 32. London: NICE.
96. -. 2008. NICE Response to the Health Select Committee's Report. London: NICE.
97. No Flexibility in U.K. NICE Advice. 1999. Scrip, May 21, 6.
98. No Viagra Reimbursement in EU? 1998. Scrip, July 10, 3.
99. O'Donovan, O. 2007. Corporate Colonization of Health Activism? International Journal of Health Services 37:711-733.
100. Office of Fair Trading (OFT). 2007. The Pharmaceutical Price Regulation Scheme: An OFT Market Study. London: OFT.
101. Ovretveit, J. 1993. Purchasing for Health Gain: The Problems and Prospects for Purchasing for Health Gains in the "Managed Markets" of the NHS and other European Health Systems. European Journal of Public Health 3:77-84.
102. Penn, R. G. 1979. The State Control of Medicines. British Journal of Clinical Pharmacology 8:295-299.
103. Pharmaceutical Society of Great Britain (PSGB). 1950a. Annual Report of the ABPI. Pharmaceutical Journal 163:301.
104. -. 1950b. Pharmaceutical Industry and Export Drive. Pharmaceutical Journal 164:11.
105. -. 1954. ABPI Annual Dinner. Pharmaceutical Journal 172:312.
106. -. 1956a. British Pharmaceutical Industry. Pharmaceutical Journal 176:239.
107. -. 1956b. Recruitment by the Industry. Pharmaceutical Journal 176:1.
108. -. 1959. Testing New Drugs. Pharmaceutical Journal 183:1.
109. -. 1961. Evidence by Advertising Inquiry Council' Pharmaceutical Journal 186:155.
110. -. 1962a. Clinical Trials of Drugs. Pharmaceutical Journal 188:429.
111. -. 1962b. Drug Toxicity: Debate on Drug Control. Pharmaceutical Journal 189:523-524.
112. -. 1962c. Hot Milk at Bedtime? Pharmaceutical Journal 189:174.
113. -. 1962d. 'Magnificent' Export Performance. Pharmaceutical Journal 189:445.
114. -. 1963a. Committee on Safety of Drugs: Members and Terms of Reference. Pharmaceutical Journal 190:534.
115. -. 1963b. Committee on Safety of Drugs: Memo to Manufacturers and Importers. Pharmaceutical Journal 191:433.
116. -. 1967. Safety of Drugs: Committee's Annual Report. Pharmaceutical Journal 199:59-60.
117. -. 1968a. Medicines Bill. Pharmaceutical Journal 200:368-389.
118. -. 1968b. The Medicines Bill in Committee. Pharmaceutical Journal 200:334-345.
119. -. 1970. Medicines Act Reassurance for Manufacturers. Pharmaceutical Journal 204:48.
120. -. 1976. CSM Asked to Speed Up Procedures. Pharmaceutical Journal 217:46.
121. Pirmohamed, M., A. M. Breckenridge, N. Kitteringham, and B. K. Park. 1998. Fortnightly Review: Adverse Drug Reactions. BMJ 316:1295-1298.
122. Pollock, A. 2004. NHS Plc: The Privatisation of Our Health Care. London: Verso.
123. Public Accounts Committee. 1983. Dispensing of Drugs in the NHS. London: HMSO.
124. Public Records Office (PRO). 1950a. Letter from Sir J. H. Woods, Board of Trade, to Sir William Douglas, MoH, July 20. MH 133/76, London.
125. -. 1950b. Letter, Sir William Douglas to Sir J. Woods, Board of Trade, July 28. MH 133/76, London.
126. -. 1950c. Memorandum from J. S. Walmsley, Secretary of the PAGB to the MoH Regarding the Second Interim Report of the JCP, June 14. MH 133/76, London.
127. -. 1950d. Note of discussion on 8 June between MoH and ABPI. MH 133/76, London.
128. -. 1951. Review of Drug Legislation. MH 58/688, London.
129. Range of Post-Marketing Surveillance Schemes Revealed at WHO Symposium. 1978. Scrip, December 9, 14-15.
130. Richards, T. 2008. Border Crossing: Purely Medicinal? BMJ 336:693.
131. Rivett, G. 1998. From Cradle to Grave: Fifty Years of the NHS. London: King's Fund.
132. Robertson, K. G. 1982. Public Secrets: A Study in the Development of Government Secrecy. London: Macmillan.
133. Sainsbury Committee. 1967. Report of the Committee of Enquiry into the Relationship of the Pharmaceutical Industry with the National Health Service, 1965-1967. Cmnd 3410. London: HMSO.
134. Scrip World Pharmaceutical News. 1988a. 1279, February 3, 3.
135. -. 1988b. 1270, January 1, 24.
136. -. 1991. 1635, July 19, 2.
137. Sculpher, M., M. Drummond, and B. O'Brien. 2001. Effectiveness, Efficiency, and NICE: A NICE Start, but Evidence Costs Money. BMJ 322:943-944.
138. Silverman, M., and P. R. Lee. 1974. Pills, Profits and Politics. Berkeley: University of California Press.
139. Sloan, F. A., K. Whetten-Goldstein, and A. Wilson. 1997. Hospital Pharmacy Decisions, Cost-Containment, and the Use of Cost-Effectiveness Analysis. Social Science and Medicine 45:523-533.
140. Stieb, E. W. 1966. Drug Adulteration. Milwaukee: University of Wisconsin Press.
141. Sudlow, C., and C. Counsell. 2003. Problems with UK Government's Risk Sharing Scheme for Assessing Drugs for Multiple Sclerosis. BMJ 326:388-392.
142. Taylor, D., and M. Bury. 2007. Chronic Illness, Expert Patients, and Care Transition. Sociology of Health and Illness 29:27-45.
143. Temin, P. 1980. Taking Your Medicine: Drug Regulation in the United States. Cambridge, MA: Harvard University Press.
144. Thompson, G. 1984. Rolling Back the State? Economic Intervention 1975-82. In State and Society in Contemporary Britain, ed. G. McLennan, D. Held, and S. Hall, 279-298. Cambridge, U.K.: Polity Press.
145. Topol, E. J. 2004. Failing the Public Health - Rofecoxib, Merck, and the FDA. New England Journal of Medicine 351:1707-1709.
146. Tuohy, C. H. 2003. Agency, Contract, and Governance: Shifting Shapes of Accountability in the Health Care Arena. Journal of Health Politics, Policy and Law 28:195-215.
147. U.K. Rules DoH Viagra Circular Unlawful. 1999. Scrip, May 28, 4.
148. U.S. Congress. 1984. Prescription Drug Advertising to Consumers: Staff Report. House Committee on Energy and Commerce, Subcommittee on Oversight and Investigation. Washington, DC: GPO.
149. U.S. Insurers Turn Down Viagra Citing Lack of Safety Data. 1998. Scrip, July 10, 14.
150. Viagra Breaks All Records in the U.S. 1998. Scrip, May 1, 20.
151. Viagra Recommended for EC Approval. 1998. Scrip, May 27-29, 36.
152. Wade, O. L. 1983. Achievements, Problems, and Limitations of Regulatory Bodies. In Medicines Review Worldwide - A Patient Benefit or a Regulatory Burden? Proceedings of the Fifth Annual Symposium of the British Institute of Regulatory Affairs, ed. D. Farrell, 2-9. London: British Institute of Regulatory Affairs.
153. Walker, S. R., and C. E. Lumley. 1987. Reporting and Under-Reporting. In Adverse Drug Reactions, ed. R. D. Mann, 124-135. Carnforth, U.K.: Parthenon.
154. Walshe, K., and T. G. Rundall. 2001. Evidence-Based Management: From Theory to Practice in Health Care. Milbank Quarterly 79:429-457.
155. Webster, C. 1998. The National Health Service: A Political History. Oxford: Oxford University Press.
156. Wheeler, D. E. 1964. President's Statement. ABPI Annual Report (1963-64), 2-3. London: ABPI.
157. Why Not Zanamivir? 2001. Drug and Therapeutics Bulletin 39:9-10.
158. Williams, I. P., and S. Bryan. 2007. Cost-Effectiveness Analysis and Formulary Decision-Making in England. Social Science and Medicine 65:2116-2129.
159. Wilson, A. B. 1977. Post-Marketing Surveillance of Adverse Reactions to New Medicines. BMJ 2:1002.
160. Woman Wins Herceptin Court Fight. 2006. BBC News, April 12. news.bbc.co.uk/2/ hi/health/4902150.stm.
161. Women Caught in Cancer Care Lottery. 1998. BBC News, October 29. news.bbc .co.uk/2/hi/health/203494.stm.